Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis
May 17, 2022Toronto, ON, May 17, 2022 - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomide™ tablets, a generic version of Aubagio®, for the treatment of relapsing remitting multiple sclerosis (RRMS).
Apotex’s teriflunomide is a once-daily monotherapy indicated to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability for patients with RRMS.
“We are pleased to provide Canada’s multiple sclerosis patient community with a generic option of oral treatment,” said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets. “With this launch, patients will gain access to high-quality, Canadian-made medication, at an affordable price.”
Canada leads the world with one of the highest rates of multiple sclerosis, with an estimated 90,000 Canadians living with the disease. On average, 12 Canadians are diagnosed with MS every day. The addition of APO-Teriflunomide™ increases our existing MS product portfolio to three products including APO-Fingolimod™ and APO-Dimethyl Fumarate™.
Apo-Teriflunomide is part of the ApoAssist® comprehensive patient support program helping patients and healthcare professionals with reimbursement navigation, financial assistance for eligible patients, and coverage renewals, in addition to product-specific patient support services.
About Apotex Inc.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilars; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.
For all media inquiries, please contact:
Jordan Berman
Vice-President, Global Corporate Affairs
PH: 416-401-7487
Mobile: 647-272-2287
APO-Teriflunomide, APO-Fingolimod and APO-Dimethyl Fumarate are trademarks owned by Apotex Inc.
Aubagio is a registered trademark of Sanofi. ApoAssist is a registered trademark owned by Apotex Inc.
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
May 20, 2025
Apotex publishes 2024 Sustainability Report, highlighting progress and achievements in environmentally sustainable manufacturing, responsible business practices, and social impact
Apotex's 2024 Sustainability Report underscores our commitment to advancing health and unlocking new possibilities through partnerships, while championing sustainability and responsible business practices. "As we continue to execute our Journey of Health growth strategy, our focus on sustainability ensures that we are meeting the needs of patients, physicians, and pharmacists, and contributing positively to the environment and society. This report reflects our dedication to these values, and to transparency, accountability, and long-term value creation," said Allan Oberman, President & CEO, Apotex.
-
May 13, 2025
Apotex announces grant to Foundation for Mother and Child Health to promote maternal health with CAD $100,000 in annual funding
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, yesterday announced a grant through the Apotex Global Health Access Fund to the Foundation for Mother and Child Health ("FMCH") in Mumbai, India to support programs that promote maternal health and address child malnutrition.
-
May 13, 2025
Apotex announces $100,000 in annual funding to advance maternal and infant health in Mexico
Mexico City - Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, today announced a grant through the Apotex Global Health Access Fund to Vida y Familia México, I.A.P. ("VIFAC") to support programs that promote maternal and child health and address health disparities.